XML 19 R10.htm IDEA: XBRL DOCUMENT

Other Current Assets	9 Months Ended
Other Current Assets	Sep. 30, 2020
Other Current Assets
Other Current Assets	4. Other Current Assets As of September 30, 2020, other current assets included prepaid expenses of $1.3 million, comprised primarily of prepayments made for the Company's clinical trials for BP1002 in lymphoma and prexigebersen-A in solid tumors of $0.5 million, prepaid insurance of $0.4 million, prepaid expenses of $0.2 million related to the Company's At-The-Market Offering Agreement (the "Offering Agreement") with H. C. Wainwright & Co., LLC ("Wainwright") as described below in Note 7, prepayments for BP1003 testing activities of $0.1 million and other prepaid expenses of $0.1 million. As of December 31, 2019, other current assets included prepaid expenses of $0.8 million, comprised primarily of prepayments made for the Company's clinical trials for prexigebersen in AML and CML of $0.6 million and prepaid insurance of $0.2 million.